Osteosarcoma and Ewing Sarcoma: Choosing Limb Salvage Over Amputation

Dr. Danewa explained that CAR T-cell therapy targets surface antigens on the cancer cell itself, such as CD19 or CD22 in ALL: a patient's own T cells are removed, engineered to recognize that antigen, and returned to attack the cancer directly. Because cancer cells can develop antigen escape by losing one target, dual CAR T-cell therapy now targets CD19 and CD22 together, and similar antigen-targeted approaches (anti-GD2) are being developed for neuroblastoma and, increasingly, for brain tumors.

Only about 1% of pediatric tumors are familial or have an identifiable genetic cause. Most arise from spontaneous mutations that the body's own immune checkpoints fail to catch. There is no equivalent of smoking or alcohol as a modifiable risk factor in children, and no established viral cause, so there is currently no basis for a preventive vaccine.

Dr. Danewa recommended Nathan and Oski's Hematology and Oncology of Infancy and Childhood as the primary reference, alongside Lanzkowsky's Manual of Pediatric Hematology and Oncology, and offered to share his own treatment protocols and presentations directly with any doctor who requests them.

For relapsed ALL, inotuzumab and blinatumomab are both available. Inotuzumab is the more affordable option since it only requires day-care admission, roughly 10,000 to 12,000 US dollars per cycle (day 1, 8 and 15), and some manufacturers offer buy-one-get-one support schemes. Blinatumomab is costlier, at 30 to 40 lakh Indian rupees, because it requires 28 days of hospitalization with continuous infusion, so it is used far less often for international patients. Anti-GD2 therapy (dinutuximab) for neuroblastoma runs around 70 to 80 lakh rupees, though the price has been coming down.

Dr. Danewa put inotuzumab at roughly 10,000 to 12,000 US dollars per cycle, noted that the 70 to 80 lakh rupee cost of dinutuximab converts to about 80,000 US dollars, and priced brentuximab plus nivolumab immunotherapy for Hodgkin lymphoma in a similar range to inotuzumab, around 12,000 to 15,000 US dollars.

A longitudinal scar keeps limb-salvage surgery possible when definitive treatment follows. A transverse scar forces the removal of substantially more surrounding muscle at that later surgery, and can rule out salvage altogether.

No. Osteosarcoma is radio-resistant, so radiotherapy plays no role in its treatment. Ewing sarcoma does respond to radiation, and it forms part of standard treatment for that disease.

A randomized trial that simply shortened the interval between chemotherapy cycles, dose-dense scheduling rather than a new drug, raised survival from 65% to 73%, at the cost of needing more intensive supportive care for fever and febrile neutropenia between cycles.

It should not be. Limb-salvage surgery is now available and should be the first option pursued. Amputation is meant as a last resort when limb salvage is not possible, not a default choice made for lack of access to limb-salvage expertise.